A chimeric oncolytic poxvirus overcomes barriers to systemic cancer virotherapy

Cancer treatment has long relied on the idea of using the body's own defenses to fight disease, but one promising approach faces a stubborn obstacle: the immune system is too good at its job. Scientists have developed viruses that can seek out and destroy cancer cells, a strategy known as oncolytic virotherapy. These viruses act like microscopic hunters, infecting only the tumor and bursting the cells open. However, when doctors try to deliver these viruses through a vein to reach tumors scattered throughout the body, the patient's immune system often neutralizes them before they can do any harm. The body recognizes the virus as an invader, creates antibodies to block it, and clears it from the bloodstream. This makes it incredibly difficult to treat cancers that have spread, as the medicine never reaches its target. The challenge, then, is to engineer a virus that is strong enough to survive this immune assault, spread effectively through the tumor, and trigger a powerful attack against the cancer without being stopped by the body's natural defenses.

A team of researchers at Transgene in France has taken a different path to solve this problem. Instead of carefully designing a virus on a computer, they used a process called directed evolution, essentially letting nature select the best version of the virus through trial and error. They started with a library of sixteen different poxviruses, a family of viruses that includes the one used to eradicate smallpox. They mixed these viruses together and infected human lung cancer cells in a laboratory dish. The goal was to force the viruses to compete against one another. They harvested the viruses after a very short time, allowing only the fastest and most aggressive variants to survive and reproduce. They repeated this process over and over, applying strict conditions that favored viruses capable of killing cells quickly and spreading efficiently. After nine rounds of this intense selection, they isolated a single, unique virus they named PoxSTG.

This new virus is a genetic mosaic, a chimera created from six different parent viruses, including strains of rabbitpox, cowpox, and several types of vaccinia virus. When the researchers sequenced its DNA, they found that it had stitched together the most useful parts of its ancestors into a single, cohesive genome. The result was a virus that behaved differently from any of its parents. In tests with human cancer cells, PoxSTG replicated much faster and killed the cells more effectively than the standard vaccinia virus used in previous clinical trials. Crucially, it remained safe for normal, healthy cells, showing a strong preference for attacking only the cancerous tissue. This selectivity is vital for safety, ensuring the treatment harms the tumor without damaging the rest of the body.

One of the most striking features of PoxSTG is how it spreads. Most viruses move from cell to cell by releasing particles that float through the fluid between them, but this new virus has developed two powerful methods to bypass the barriers that usually stop it. First, it causes infected cells to fuse together, forming giant, multi-nucleated structures called syncytia. This allows the virus to move directly from one cell to another without ever entering the space where antibodies might catch it. Second, it produces a massive amount of a specific type of viral particle that is better at traveling through tissues and evading the immune system. In the lab, this virus produced twenty to forty times more of these travel-ready particles than the standard virus. This combination of direct cell-to-cell fusion and enhanced travel capability allowed the virus to spread through tumors much more thoroughly than ever before.

Perhaps the most significant breakthrough is how PoxSTG handles the immune system. When the researchers tested the virus against human blood serum, the standard virus was almost completely neutralized, losing nearly all of its ability to infect cells. In contrast, PoxSTG retained most of its infectivity, showing a remarkable ability to resist the antibodies and complement proteins that usually destroy viruses. This resistance was confirmed using blood samples from patients who had previously received a similar virus therapy; while their blood effectively blocked the old virus, it had little effect on PoxSTG. This suggests that the new virus could potentially be given repeatedly to a patient without the body immediately shutting it down, a major hurdle for current treatments.

The virus also changes the way cancer cells die. Instead of simply bursting and disappearing, the infected cells undergo a specific type of inflammatory death called pyroptosis. This process causes the cells to swell and pop, releasing signals that alert the body's immune system to the presence of cancer. The researchers found that PoxSTG triggers this response by activating a specific pathway inside the cell that leads to the formation of pores in the cell membrane. This type of death is highly visible to the immune system, effectively turning the tumor into a beacon that attracts the body's own T-cells to attack. In experiments with mice, the virus not only shrank the tumors where it was injected but also reached and destroyed distant, untreated tumors, a sign that it had successfully traveled through the bloodstream and triggered a systemic immune response against the cancer.

To test if this platform could be improved further, the researchers added a gene that produces a protein called interleukin-12, which helps boost the immune system's ability to fight cancer. When they tested this armed version of PoxSTG in mice with aggressive melanoma, it performed significantly better than a similar virus based on the standard strain. The new virus delayed tumor growth and extended the lives of the animals more effectively, demonstrating that the improved backbone can carry additional therapeutic tools. The study also showed that the virus was able to stimulate a strong immune response specifically against the tumor, without increasing the body's reaction against the virus itself. This balance is critical, as it means the virus can keep working inside the tumor while the immune system focuses its fire on the cancer.

The researchers acknowledge that while the results in mice and human cells are promising, more work is needed to ensure the virus is safe and effective in people. The virus is a complex genetic mix, and its long-term stability will need to be carefully monitored. However, the study provides a strong proof of concept that directed evolution can create a virus with properties that do not exist in nature. By combining the speed of evolution with the precision of genetic engineering, the team has produced a candidate that overcomes the primary barriers to delivering virus-based cancer therapy through the bloodstream. If these findings hold true in human trials, PoxSTG could offer a new way to treat cancers that have spread throughout the body, turning a once-impossible delivery challenge into a viable treatment strategy.